AstraZeneca Pharma India Limited announced plans to launch Palivizumab (Synagis) in India this October. The company’s stocks were trading at ₹6,730, up by ₹13.75 (0.20 per cent) as of 10.23 ...

Background: Since its introduction, palivizumab has been used to prevent respiratory syncytial virus (RSV) infection in high-risk populations. Recommendations for palivizumab administration ...

Hedge-fund powerhouse Two Sigma is likely to pay as much as $100 million to settle a Securities and Exchange Commission investigation into a trading scandal at the firm. The New York firm would ...

In spite of a significant reduction in the administration rate of palivizumab between the pre-2014 guideline and post-2014 guideline period, we did not find a significant increase in the RSV ...

That means offering palivizumab – an older, more expensive antibody taken monthly during RSV season – to high-risk infants only, including babies born prematurely or with chronic lung and ...

The traditional full line pharmacy wholesale distribution business, retail and private label products. Also has national Presence in the hospital pharmacy distribution market, and through its ...

Sobi has completed the acquisition of AstraZeneca’s Synagis (palivizumab) for $1.5 billion in cash and shares, plus certain conditional payments. As part of the deal, first announced in August ...

It is the first approval for Beyfortus (nirsevimab) by any regulatory authority. AZ's Synagis (palivizumab) is currently the only approved drug in Europe to provide passive prophylaxis against RSV ...

That medicine - palivizumab was previously funded for at-risk babies using money ring-fenced for the Covid-19 response, and was shown to cut hospitalisations. But that funding ended in October 2023, ...

List your movie, TV & celebrity picks.